Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorouracil SCHEMBL8778444 | 0.84 | LMNA (0.51) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| 5-Bromouracil SCHEMBL4201154 | 0.80 | PYGM (0.39) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2641583 | 0.76 | TK1 (0.41) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12642442 | 0.76 | TK1 (0.41) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL658719 | 0.76 | TK1 (0.41) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL23892079 | 0.76 | TK1 (0.41) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| 5-Bromouracil SCHEMBL29805 | 0.71 | — | — | |
| SCHEMBL3807107 | 0.71 | — | — | |
| SCHEMBL10807564 | 0.71 | — | — | |
| SCHEMBL13981782 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | TK1 732/4885LMNA 3366/4885SMN1; SMN2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.